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Interfaces have always been of concern with respect to the
delivery of bioactives. Interfaces within the delivery system
that can affect stability are a concern; however, there are other
interfaces of importance, such as the interface with the body
tissue, the regulatory interface and the emerging interface when
drug delivery is linked to e-health applications. This presen-
tation will address all these interfaces covering basic science
aspects as well as discussion of e-health applications. There
are interfaces between different phases in formulations such
as emulsions, foams, suspensions etc. There are interfaces
between actives and excipients within a formulation.The actives
as well as excipients may be in different states. The inter-
faces can be areas of weakness within a formulation with
consequent stability concerns resulting from phase change,
and incompatibilities such as relative hydrophilicity/lipophilicity.
The interface between the body and the delivery system can
vary with the dosage form characteristics as well as the route
of administration. The tissue/device interface has implica-
tions in the foreign body response or lack thereof. Another
important interface is that between the industry and the regu-
latory authorities, and what we need to understand in terms
of device performance testing and safety. With the e-health
revolution, it is important to understand the implication to
drug delivery science. This presentation will focus on: 1) for-
mulation issues related to stability at interfaces; 2) the interface
of drug delivery devices with the body and overcoming the
foreign body response; and 3) the interface with the regula-
tory authorities in terms of performance indicating tests for
controlled release parenteral products; and 4) the e-health
interface.
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